Rocket Pharmaceuticals is a clinical-stage gene therapy company developing treatments for rare genetic diseases, often using lentiviral or AAV-based platforms. Its pipeline has focused on serious conditions such as certain inherited blood, heart and immune disorders where a one-time genetic correction could address the root cause. The company serves rare-disease patients and specialist physicians for whom few durable therapies exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -61.3 | — |
| Q2 2025 | 0 | — | -68.9 | — |
| Q3 2025 | 0 | — | -50.3 | — |
| Q4 2025 | 0 | — | -42.5 | — |
| Q1 2026 | 0 | — | -47.6 | — |
| Q2 2026 | 0 | — | 123.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cabaletta Bio, Inc. (CABA), FB Bancorp, Inc. (FBLA), Melar Acquisition Corp. I (MACI), Cue Biopharma, Inc. (CUE), NewHold Investment Corp III (NHIC), Chicago Atlantic Real Estate Finance, Inc. (REFI)